I-Mab to Participate at the Truist Securities BioPharma Symposium
Rhea-AI Summary
I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on cancer immunotherapies, has announced its participation in the Truist Securities BioPharma Symposium on November 7, 2024. The company's management team, including Interim CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis, and Senior Director of Investor Relations Tyler Ehler, will engage in one-on-one and small group meetings with investors during the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IMAB gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Event Details
Meeting Date | Thursday, November 7, 2024 |
Meetings | One-on-one and small group meetings: November 7, 2024 |
Management | Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO) Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html
SOURCE I-Mab Biopharma
FAQ
When is I-Mab (IMAB) participating in the Truist Securities BioPharma Symposium?
Which executives from I-Mab (IMAB) will attend the Truist Securities BioPharma Symposium?
What type of meetings will I-Mab (IMAB) conduct at the Truist Securities BioPharma Symposium?
What is I-Mab's (IMAB) primary business focus?
